Search Within

Neha Sanat Korde

  1. "Advanced Practice Providers"
Formats
  1. Meeting Abstract (11)
  2. Journal Article (4)
Groups
  1. Advanced Practice Providers (15)
  2. Bone Marrow Transplant (15)
  3. Center for Hematologic Malignancies (15)
  4. Department of Medicine (15)
  5. Hematologic Malignancies, Division of (15)
  6. Myeloma (15)

More Groups

People
  1. Alexander Lesokhin (14)
  2. Sham Mailankody (14)
  3. David Chung (13)
  4. Gunjan Shah (13)
  5. Hani Hassoun (13)
  6. Heather Landau (13)

More People

Years
  1. 2024 (2)
  2. 2021 (3)
  3. 2020 (2)
  4. 2019 (2)
  5. 2018 (4)
  6. 2017 (2)
Publications
  1. Blood (9)
  2. Biology of Blood and Marrow Transplantation (2)
  3. Blood Advances (1)
  4. Clinical Lymphoma, Myeloma and Leukemia (1)
  5. JAMA Oncology (1)
  6. Scientific Reports (1)
Publishers
  1. American Society of Hematology (10)
  2. Elsevier Inc. (3)
  3. American Medical Association (1)
  4. Nature Publishing Group (1)

Results (15)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Manufacture of anti-BCMA CAR T cell is feasible after salvage autologous or allogeneic hematopoietic stem cell transplantation
    Meeting Abstract

    Shah, G. L.; Perica, K.; Nagel, K.; Payson, E.; Hosszu, K. K.; Chung, D. J.; Landau, H. J.; Scordo, M.; Hultcrantz, M.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies
    Journal Article

    Howard, A. J.; Concepcion, I.; Wang, A. X.; Hamadeh, I. S.; Hultcrantz, M.; Mailankody, S.; Tan, C.; Korde, N.; Lesokhin, A. M.; Hassoun, H.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Oncologic immunomodulatory agents in patients with cancer and COVID-19
    Journal Article

    Jee, J.; Stonestrom, A. J.; Devlin, S.; Nguyentran, T.; Wills, B.; Narendra, V.; Foote, M. B.; Lumish, M.; Vardhana, S. A.; Pastores, S. M.; more...
    Scientific Reports (2021)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Final results of a phase I clinical trial
    Meeting Abstract

    Mailankody, S.; Ghosh, A.; Staehr, M.; Purdon, T. J.; Roshal, M.; Halton, E.; Diamonte, C.; Pineda, J.; Anant, P.; Bernal, Y.; more...
    Blood (2018)

    Fulltext@MSK | Save